Who are Rifaximin and loperamide's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rifaximin-and-loperamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Rifaximin and loperamide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rifaximin and loperamide (Rifaximin and loperamide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic + antidiarrheal combination. Area: Gastroenterology.

marketed Antibiotic + antidiarrheal combination Bacterial RNA polymerase (rifaximin); mu-opioid receptors in the GI tract (loperamide) Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Rifaximin and loperamide (Rifaximin and loperamide) — The University of Texas Health Science Center, Houston. Rifaximin reduces pathogenic gut bacteria while loperamide decreases intestinal motility to reduce diarrhea symptoms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rifaximin and loperamide TARGET	Rifaximin and loperamide	The University of Texas Health Science Center, Houston	marketed	Antibiotic + antidiarrheal combination	Bacterial RNA polymerase (rifaximin); mu-opioid receptors in the GI tract (loperamide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic + antidiarrheal combination class)

The University of Texas Health Science Center, Houston · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rifaximin and loperamide — Competitive Intelligence Brief. https://druglandscape.com/ci/rifaximin-and-loperamide. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab